Ambalal Sarabhai Enterprises News

Ambalal Sarabhai Enterprises' Joint Venture CoSara Diagnostics Explores SPAC Transaction

Ambalal Sarabhai Enterprises Limited announced that Co-Diagnostics Inc., its joint venture partner in CoSara Diagnostics Pvt. Ltd., has engaged Maxim Group LLC as exclusive financial advisor to explore strategic alternatives for the Indian joint venture. The options include a potential merger with a Special Purpose Acquisition Company (SPAC) or similar entity listed on a U.S. national securities exchange. CoSara Diagnostics, established in 2017, is a joint venture between Co-Diagnostics Inc. and Synbiotics Ltd., with the latter being a group company of Asence Inc., both subsidiaries of Ambalal Sarabhai Enterprises. The joint venture focuses on manufacturing and selling molecular diagnostics products to patients and healthcare providers in international markets, with initial focus on India. Co-Diagnostics CEO Dwight Egan stated the company aims to unlock value for CoSara and shareholders while helping the venture realize its founding vision.

Ambalal Sarabhai's Telerad Division Wins Best Regional Distributor Award at Broadcast India Show 2025

Ambalal Sarabhai Enterprises Limited announced that its Telerad division, which operates under Systronics India Limited, received the 'Best Regional Distributor — Broadcast - West Award' at the Broadcast India Show 2025 held in Mumbai in October 2025. Telerad is described as a total solution company and leading system integrator that provides complete end-to-end solutions in broadcast segments. The award recognizes Telerad's leadership in delivering innovative broadcast solutions and exceptional services to industries.

Ambalal Sarabhai Enterprises Reports Strong Q1 Performance with 822.35 Lakhs Net Profit, Forms New Pharma Committee

Ambalal Sarabhai Enterprises Limited reported consolidated net profit of Rs. 822.35 lakhs for the quarter ended June 30, 2025, compared to Rs. 34.71 lakhs in the same period last year. Revenue from operations stood at Rs. 4,033.88 lakhs versus Rs. 4,069.66 lakhs in the previous year quarter. The company operates in two segments: Pharmaceuticals generated Rs. 2,546.42 lakhs revenue while Electronics contributed Rs. 1,487.46 lakhs. On a standalone basis, the company posted profit after tax of Rs. 690.85 lakhs compared to Rs. 46.33 lakhs in the corresponding quarter. The Board constituted a new Pharma Committee comprising Mr. Kartikeya V. Sarabhai, Mr. Mohal K. Sarabhai, and Mr. Govindprasad Namdeo to oversee pharmaceutical business operations including strategic review, compliance oversight, and business performance monitoring. Earnings per share improved to Rs. 1.07 from Rs. 0.05 in the year-ago quarter.

Ambalal Sarabhai's Telerad Division Partners with Bolin Technology

Ambalal Sarabhai Enterprises announced that the Telerad division of its subsidiary has signed an agreement with Bolin Technology. Through this partnership, Bolin enters the Indian market with Telerad as the exclusive distributor for their PTZ camera and AV-over-IP solutions in India.